$OMED Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinumresistant Ovarian Cancer ESMO18 httpwww.oncomed.cominvestreleasedetail.cfmReleaseID1079501Â
$OMED Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer #ESMO18 http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1079501 …
More From BioPortfolio on "$OMED Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer #ESMO18 http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1079501 …"